Veracyte Inc Overview
Industry: Diagnostics & Research
Sector: Healthcare
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer di Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Veracyte Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $135.1M (+26% YoY). Operating income was $22.6M (+680% YoY). Net income was $28.7M (+20.6% YoY).
Revenue
$135.1M
+26% YoY
Operating income
$22.6M
+680% YoY
Net income
$28.7M
+20.6% YoY
Adjusted EBITDA
$42.8M
reported
What changed
- Revenue +26% YoY to $135.1M.
- Operating income +680% YoY to $22.6M.
- Net income +20.6% YoY to $28.7M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 06, 2026
SEC filing
8-K
May 05, 2026
SEC filing
10-K
Feb 26, 2026
Earnings release
Earnings release
Feb 25, 2026
SEC filing
8-K
Feb 25, 2026
SEC filing
8-K
Jan 12, 2026
Earnings release
Earnings release
Jan 12, 2026
SEC filing
10-Q
Nov 05, 2025
SEC filing
8-K
Nov 04, 2025
Earnings release
Earnings release
Nov 04, 2025
SEC filing
10-Q
Aug 07, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
Headline from Yahoo Finance: Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline.
Piper Sandler initiates Veracyte stock with overweight rating By Investing.com
Headline from Investing.com Nigeria: Piper Sandler initiates Veracyte stock with overweight rating By Investing.com.
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Headline from Benzinga: This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday.
Piper Sandler initiates Veracyte stock with overweight rating
Headline from Investing.com: Piper Sandler initiates Veracyte stock with overweight rating.
Earnings Per Share
Score 2.00/5
Veracyte Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Diagnostics & Research industry
, IQVIA Holdings Inc
, Agilent Technologies Inc
, Thermo Fisher Scientific Inc
are companies with high ratings.
Return on Equity
Score 3.10/5
Veracyte Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.08/5
Veracyte Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 4.00/5
Veracyte Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios